These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3921077)

  • 1. Valproic acid and active unsaturated metabolite (2-en): transfer to mouse liver following human therapeutic doses.
    Nau H; Loscher W
    Biopharm Drug Dispos; 1985; 6(1):1-8. PubMed ID: 3921077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences.
    Löscher W; Nau H
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):192-202. PubMed ID: 6435554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.
    Nau H
    Teratology; 1986 Feb; 33(1):21-7. PubMed ID: 3090732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system.
    Nau H; Zierer R
    Biopharm Drug Dispos; 1982; 3(4):317-28. PubMed ID: 6819013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.
    Rettenmeier AW; Prickett KS; Gordon WP; Bjorge SM; Chang SL; Levy RH; Baillie TA
    Drug Metab Dispos; 1985; 13(1):81-96. PubMed ID: 2858383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy.
    Löscher W; Nau H; Marescaux C; Vergnes M
    Eur J Pharmacol; 1984 Mar; 99(2-3):211-8. PubMed ID: 6428923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice.
    Keane PE; Simiand J; Morre M
    Methods Find Exp Clin Pharmacol; 1985 Feb; 7(2):83-6. PubMed ID: 2859407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment.
    Löscher W; Nau H
    J Pharmacol Exp Ther; 1983 Sep; 226(3):845-54. PubMed ID: 6411902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
    Lewandowski C; Klug S; Nau H; Neubert D
    Arch Toxicol; 1986 Apr; 58(4):239-42. PubMed ID: 3087328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
    Kassahun K; Baillie TA
    Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes.
    Aires CC; Soveral G; Luís PB; ten Brink HJ; de Almeida IT; Duran M; Wanders RJ; Silva MF
    FEBS Lett; 2008 Oct; 582(23-24):3359-66. PubMed ID: 18775709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
    Tang W; Abbott FS
    Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid.
    Hauck RS; Nau H
    Toxicol Lett; 1989 Oct; 49(1):41-8. PubMed ID: 2510370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.
    Kondo T; Otani K; Hirano T; Kaneko S; Fukushima Y
    Br J Clin Pharmacol; 1990 Jan; 29(1):116-9. PubMed ID: 2105099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticonvulsant activity of metabolites of valproic acid.
    Löscher W
    Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):158-63. PubMed ID: 6784685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capillary GCMS assay of 2-n-propyl-4-pentenoic acid (4-ene VPA) in rat plasma and urine.
    Singh K; Abbott FS; Orr JM
    Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):211-23. PubMed ID: 3602586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Lockard JS; Thummel KE; Baillie TA
    Drug Metab Dispos; 1986; 14(4):443-53. PubMed ID: 2873992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice.
    Löscher W; Nau H
    Arch Int Pharmacodyn Ther; 1982 May; 257(1):20-31. PubMed ID: 6810778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.